Brahimi F, Nassour H, Galan A, Guruswamy R, Ortiz C, Nejatie A
PNAS Nexus. 2025; 4(2):pgaf020.
PMID: 39911316
PMC: 11795507.
DOI: 10.1093/pnasnexus/pgaf020.
Chen Y, Su C, Cai Y, Ke L, Huang Y
Sci Rep. 2025; 15(1):2442.
PMID: 39828780
PMC: 11743774.
DOI: 10.1038/s41598-025-85888-1.
Kim M, Lee W, Jin W
Cell Mol Life Sci. 2023; 80(10):303.
PMID: 37749450
PMC: 10520132.
DOI: 10.1007/s00018-023-04960-z.
Kim M, Lee W, Park Y, Jin W
Cell Death Dis. 2022; 13(10):850.
PMID: 36202793
PMC: 9537181.
DOI: 10.1038/s41419-022-05298-3.
Kim M, Lee W, Lee H, Jin W
Cell Death Dis. 2022; 13(9):836.
PMID: 36171207
PMC: 9519565.
DOI: 10.1038/s41419-022-05275-w.
Role of the long non-coding RNA LINC00052 in tumors.
Xiong D, Wang D, Chen Y
Oncol Lett. 2021; 21(4):316.
PMID: 33692848
PMC: 7933760.
DOI: 10.3892/ol.2021.12577.
Implication of TrkC-miR2 in neurotrophin signalling pathway regulation through NGFR transcript targeting.
Dokaneheifard S, Soltani B
J Cell Mol Med. 2021; 25(7):3381-3390.
PMID: 33675128
PMC: 8034437.
DOI: 10.1111/jcmm.16415.
Genome-wide analysis identifies critical DNA methylations within NTRKs genes in colorectal cancer.
Chen Z, Huang Z, Luo Y, Zou Q, Bai L, Tang G
J Transl Med. 2021; 19(1):73.
PMID: 33593392
PMC: 7885252.
DOI: 10.1186/s12967-021-02740-6.
MiRNA-128-3p Restrains Malignant Melanoma Cell Malignancy by Targeting NTRK3.
Zhou X, He J, Wang Q, Ma T
Front Oncol. 2021; 10:538894.
PMID: 33575204
PMC: 7871904.
DOI: 10.3389/fonc.2020.538894.
Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors.
Niu Y, Lin A, Luo P, Zhu W, Wei T, Tang R
Front Pharmacol. 2020; 11:1213.
PMID: 32903385
PMC: 7434857.
DOI: 10.3389/fphar.2020.01213.
TrkB Inhibits the BMP Signaling-Mediated Growth Inhibition of Cancer Cells.
Kim M, Jin W
Cancers (Basel). 2020; 12(8).
PMID: 32731498
PMC: 7464134.
DOI: 10.3390/cancers12082095.
Relevance of Neurotrophin Receptors CD271 and TrkC for Prognosis, Migration, and Proliferation in Head and Neck Squamous Cell Carcinoma.
Foerster Y, Stover T, Wagenblast J, Diensthuber M, Balster S, Gabrielpillai J
Cells. 2019; 8(10).
PMID: 31569361
PMC: 6830344.
DOI: 10.3390/cells8101167.
TrkC-Targeted Kinase Inhibitors And PROTACs.
Zhao B, Burgess K
Mol Pharm. 2019; 16(10):4313-4318.
PMID: 31512882
PMC: 7034693.
DOI: 10.1021/acs.molpharmaceut.9b00673.
A zwitterionic near-infrared dye linked TrkC targeting agent for imaging metastatic breast cancer.
Yang Z, Usama S, Li F, Burgess K, Li Z
Medchemcomm. 2018; 9(10):1754-1760.
PMID: 30429980
PMC: 6194490.
DOI: 10.1039/c8md00190a.
An agent for optical imaging of TrkC-expressing, breast cancer.
Kamkaew A, Li F, Li Z, Burgess K
Medchemcomm. 2018; 8(10):1946-1952.
PMID: 30108715
PMC: 6071931.
DOI: 10.1039/c7md00328e.
Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial.
Danilenko M, Stamp E, Stocken D, Husain A, Zangarini M, Cranston A
JAMA Dermatol. 2018; 154(8):913-921.
PMID: 29955768
PMC: 6128505.
DOI: 10.1001/jamadermatol.2018.1610.
Copy number variations of neurotrophic tyrosine receptor kinase 3 (NTRK3) may predict prognosis of ovarian cancer.
Ge L, Li N, Liu M, Xu N, Wang M, Wu L
Medicine (Baltimore). 2017; 96(30):e7621.
PMID: 28746220
PMC: 5627846.
DOI: 10.1097/MD.0000000000007621.
TrkC promotes colorectal cancer growth and metastasis.
Kim M, Suh K, Hong S, Jin W
Oncotarget. 2017; 8(25):41319-41333.
PMID: 28455963
PMC: 5522271.
DOI: 10.18632/oncotarget.17289.
Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.
Cranston A, Stocken D, Stamp E, Roblin D, Hamlin J, Langtry J
Trials. 2017; 18(1):111.
PMID: 28270164
PMC: 5341402.
DOI: 10.1186/s13063-017-1812-z.
Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations.
Oczko-Wojciechowska M, Swierniak M, Krajewska J, Kowalska M, Kowal M, Stokowy T
Sci Rep. 2017; 7:42074.
PMID: 28181547
PMC: 5299608.
DOI: 10.1038/srep42074.